NASDAQ$CYTK
Cytokinetics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Cytokinetics reported Q2 2025 results driven by a major license milestone from its Bayer collaboration.
Cytokinetics recorded total revenues of $66.8 million in the second quarter, primarily from license and milestone payments. The company posted a net loss of $134.4 million as R&D and G&A expenses rose with ongoing clinical programs and commercial preparations. Cash and investments remained strong at over $1.0 billion supporting pipeline advancement.
- Total revenues reached $66.8 million, led by $64.4 million in license and milestone revenues from Bayer.
- Net loss narrowed to $134.4 million compared with $143.3 million in the prior-year quarter.
- R&D expenses increased to $112.6 million reflecting continued investment in aficamten and other programs.
- Cash, cash equivalents and investments totaled approximately $1.04 billion at quarter end.
Headline financials
Revenue & EPS history
Cytokinetics · Revenue · Quarterly
$66.8M
Revenue by segment
Cytokinetics · $66.8M total across 2 segments · Q2 2025
- License and milestone revenues$64.4M—96.4%
- Collaboration revenues$2.42M—3.6%
Forward guidance
Company continues to advance aficamten toward potential approval with PDUFA target action date of December 26, 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.2%
Avg return
30 days after
49%
32 / 65 earnings
Positive
+21.4%
Q4 2014
Best reaction
-17.7%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +16.8% | +16.5% | +9.5% | |
| Q4 2025 | -10.3% | -12.4% | -10.8% | |
| Q3 2025 | +1.9% | +12.4% | +10.9% | |
| Q1 2025 | -2.8% | -5.4% | -4.9% | |
| Q4 2024 | -3.1% | -7.5% | -9.0% | |
| Q3 2024 | +6.3% | +11.6% | -3.0% | |
| Q2 2024 | +8.9% | +9.5% | +5.6% | |
| Q1 2024 | -1.9% | -11.3% | -19.1% | |
| Q4 2023 | -7.5% | -6.4% | -11.3% | |
| Q3 2023 | +3.5% | +2.1% | -4.4% | |
| Q2 2023 | +6.8% | +2.8% | +15.8% | |
| Q1 2023 | +0.3% | -1.3% | -1.8% | |
| Q4 2022 | -8.7% | -9.8% | -18.8% | |
| Q3 2022 | -9.8% | -8.6% | -3.3% | |
| Q2 2022 | +21.0% | +22.5% | +26.2% | |
| Q1 2022 | +0.9% | -12.6% | +7.2% | |
| Q4 2021 | +11.7% | +14.7% | +16.3% | |
| Q3 2021 | +12.4% | +18.2% | +2.4% | |
| Q2 2021 | +7.8% | +8.2% | +10.0% | |
| Q1 2021 | +2.8% | +0.8% | -13.4% | |
| Q4 2020 | -9.7% | -6.4% | +15.0% | |
| Q3 2020 | +5.1% | +0.8% | +2.4% | |
| Q2 2020 | -2.8% | -4.7% | +2.2% | |
| Q1 2020 | -4.2% | +27.8% | +23.3% | |
| Q4 2019 | +4.4% | +1.1% | -15.4% | |
| Q3 2019 | -5.5% | -6.5% | -18.3% | |
| Q2 2019 | +1.1% | -2.0% | +5.5% | |
| Q1 2019 | +12.6% | +16.7% | +10.4% | |
| Q4 2018 | -0.8% | -2.7% | +19.2% | |
| Q3 2018 | +10.6% | +5.7% | +17.5% | |
| Q2 2018 | -5.7% | -7.0% | -9.5% | |
| Q1 2018 | +19.3% | +14.5% | +21.4% | |
| Q4 2017 | -10.8% | -13.9% | -2.8% | |
| Q3 2017 | +6.7% | +2.2% | -43.1% | |
| Q2 2017 | -5.6% | -11.2% | +3.1% | |
| Q1 2017 | -3.0% | -7.7% | -16.6% | |
| Q4 2016 | -1.7% | -9.2% | +8.3% | |
| Q3 2016 | +9.3% | +6.6% | +39.7% | |
| Q2 2016 | +7.3% | +12.8% | +18.1% | |
| Q1 2016 | +3.3% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | +13.3% | — | — | |
| Q2 2015 | -17.7% | — | — | |
| Q1 2015 | -15.7% | — | — | |
| Q4 2014 | +21.4% | — | — | |
| Q3 2014 | -1.0% | — | — | |
| Q2 2014 | -1.2% | — | — | |
| Q1 2014 | -9.5% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | -7.2% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | -1.0% | — | — | |
| Q3 2012 | -1.6% | — | — | |
| Q2 2012 | +6.3% | — | — | |
| Q1 2012 | -4.0% | — | — | |
| Q4 2009 | +0.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2011 | +3.5% | — | — | |
| Q2 2011 | -14.0% | — | — | |
| Q4 2010 | -14.0% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q3 2010 | -4.0% | — | — | |
| Q2 2010 | -14.3% | — | — | |
| Q1 2010 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro